| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Financial giants have made a conspicuous bearish move on Cytokinetics. Our analysis of options history for Cytokinetics (NASDAQ:CYTK) revealed 8 unusual trades.
Delving into the details, we found 37% of traders were bullish, while 62% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $148,711, and 5 were calls, valued at $170,948.
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $50.0 to $100.0 for Cytokinetics during the past quarter.
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Cytokinetics's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Cytokinetics's whale activity within a strike price range from $50.0 to $100.0 in the last 30 days.
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| CYTK | PUT | SWEEP | BULLISH | 06/21/24 | $60.00 | $76.1K | 386 | 62 |
| CYTK | CALL | SWEEP | BEARISH | 06/21/24 | $100.00 | $50.8K | 665 | 14 |
| CYTK | PUT | SWEEP | BULLISH | 06/21/24 | $60.00 | $45.8K | 386 | 484 |
| CYTK | CALL | TRADE | BEARISH | 03/15/24 | $100.00 | $35.0K | 9.2K | 1.1K |
| CYTK | CALL | TRADE | BEARISH | 01/17/25 | $50.00 | $29.5K | 1.5K | 10 |
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $101.0.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Cytokinetics with Benzinga Pro for real-time alerts.
Posted In: CYTK
